Ascendis制药 ASND 深 沪
等待开盘 08-01 09:30:00 美东时间
173.50
+6.720
+4.03%
华盛通- 最 高176.98
- 今 开167.40
- 成交量 60.85万股
- 最 低 167.27
- 昨 收 166.78
- 总市值 104.96亿
- 52周最高 183.00
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 111.09
- 委 比 10.07%
- 总股本 6049.42万
- 历史最高 183.98
- 量 比 1.32
- 振 幅 5.82%
- 历史最低 11.92
- 每 手 1
- 风险率 17.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ascendis wins FDA approval for growth hormone deficiency treatment
The U.S. FDA has approved Ascendis Pharma's (ASND) Skytrofa (lonapegsomatropin) as a once-weekly treatment for adults with growth hormone deficiency (GHD). Skytrofa, which acts as a replacement of end...
07-29 00:09
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
Ascendis Pharma announced FDA approval of SKYTROFA for adults with growth hormone deficiency (GHD), using weekly lonapegsomatropin-tcgd for sustained somatropin release. The approval follows Phase 3 trial results showing efficacy and safety compared to daily somatropin. SKYTROFA addresses challenges in adherence to daily injections, offering a less burdensome treatment regimen. The company aims to expand its label for rare conditions and initiate...
07-28 11:00
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 year...
07-23 07:30
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life
Ascendis Pharma announced positive Phase 3 PaTHway Trial results at Week 156, showing long-term benefits of TransCon PTH for adults with hypoparathyroidism. Key findings included sustained normalization of serum calcium in 88% of patients, independence from conventional therapy in 96%, improved kidney function (eGFR increased by 8.76 mL/min/1.73 m² overall and 13.98 mL/min/1.73 m² in patients with baseline eGFR <60), and enhanced quality of life....
07-14 20:01
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
Ascendis Pharma announced two oral presentations at ENDO 2025, highlighting long-term safety and efficacy data for treatments in hypoparathyroidism and achondroplasia. Dr. Aliya Khan presented findings from the Phase 3 PaTHway Trial, showing benefits of TransCon® PTH in adults. Dr. Carlos Bacino shared safety data from the ApproaCH Trial for TransCon® CNP in children. The company emphasized its commitment to advancing therapies for rare endocrine...
07-07 20:01
Morgan Stanley Assumes Ascendis Pharma at Overweight, Announces Price Target of $250
Morgan Stanley analyst Maxwell Skor assumes Ascendis Pharma (NASDAQ:ASND) with a Overweight rating and announces Price Target of $250.
07-04 01:23
Peering Into Ascendis Pharma's Recent Short Interest
Ascendis Pharma's (NYSE:ASND) short percent of float has fallen 20.27% since it...
07-03 23:00
Summit Therapeutics Signs Sublease with Ascendis Pharma
Summit Therapeutics ( ($SMMT) ) has shared an update. Summit Therapeutics Inc. ...
06-21 05:31
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $224
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $215 to $224.
06-13 23:11
